SG10201709967YA - Treatment regimens - Google Patents

Treatment regimens

Info

Publication number
SG10201709967YA
SG10201709967YA SG10201709967YA SG10201709967YA SG10201709967YA SG 10201709967Y A SG10201709967Y A SG 10201709967YA SG 10201709967Y A SG10201709967Y A SG 10201709967YA SG 10201709967Y A SG10201709967Y A SG 10201709967YA SG 10201709967Y A SG10201709967Y A SG 10201709967YA
Authority
SG
Singapore
Prior art keywords
treatment regimens
regimens
treatment
Prior art date
Application number
SG10201709967YA
Other languages
English (en)
Inventor
Nicolas G Sitchon
Robert E Pyke
John F Kaufmann
Original Assignee
S1 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S1 Pharmaceuticals Inc filed Critical S1 Pharmaceuticals Inc
Publication of SG10201709967YA publication Critical patent/SG10201709967YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201709967YA 2012-08-06 2013-08-06 Treatment regimens SG10201709967YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261679999P 2012-08-06 2012-08-06

Publications (1)

Publication Number Publication Date
SG10201709967YA true SG10201709967YA (en) 2018-01-30

Family

ID=50068530

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201709967YA SG10201709967YA (en) 2012-08-06 2013-08-06 Treatment regimens
SG11201500919PA SG11201500919PA (en) 2012-08-06 2013-08-06 Treatment regimens
SG10201908587P SG10201908587PA (en) 2012-08-06 2013-08-06 Treatment regimens

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201500919PA SG11201500919PA (en) 2012-08-06 2013-08-06 Treatment regimens
SG10201908587P SG10201908587PA (en) 2012-08-06 2013-08-06 Treatment regimens

Country Status (15)

Country Link
US (1) US9517254B2 (fr)
EP (1) EP2879680A4 (fr)
JP (2) JP2015524474A (fr)
KR (3) KR20230136142A (fr)
CN (2) CN104884060A (fr)
AU (2) AU2013299725A1 (fr)
BR (1) BR112015002687A2 (fr)
CA (1) CA2881388A1 (fr)
EA (1) EA201590349A1 (fr)
HK (2) HK1211239A1 (fr)
IL (1) IL237150B (fr)
MX (1) MX2015001695A (fr)
SG (3) SG10201709967YA (fr)
WO (1) WO2014025814A1 (fr)
ZA (1) ZA201501562B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933921A1 (fr) * 2016-06-17 2017-12-17 S1 Biopharma, Inc. Methodes de traitement des femmes souffrant de baisse du desir sexuel au moyen d'un traitement combinant le bupropion et la trazodone
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687771A (en) * 1985-11-01 1987-08-18 Bristol-Myers Company Method for treatment of male impotence
DE4321965A1 (de) 1993-07-01 1995-01-12 Cytech Biomedical Inc Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2002322085A (ja) 2001-04-26 2002-11-08 Kazuhito Tomizawa 知的機能障害治療剤
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
WO2004030524A2 (fr) * 2002-10-03 2004-04-15 Pr Pharmaceuticals Traitement de l'autisme et de troubles similaires
JP2007525442A (ja) * 2003-03-05 2007-09-06 ピーアール ファーマシューティカルズ，インコーポレイテッド オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法
CN1946404A (zh) * 2004-04-22 2007-04-11 贝林格尔·英格海姆国际有限公司 用于治疗性功能疾病ⅱ的新颖药物组合物
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20060004076A1 (en) 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
US20060122127A1 (en) 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20060211685A1 (en) 2005-03-04 2006-09-21 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
CA2667909A1 (fr) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Traitement des troubles pervasifs du developpement
WO2008075162A2 (fr) * 2006-12-15 2008-06-26 Pfizer Limited Composés pour le traitement d'un dysfonctionnement sexuel
WO2009016488A2 (fr) * 2007-08-02 2009-02-05 Compugen, Ltd. Compositions comprenant des antidépresseurs tétracycliques pour le traitement d'un cancer et procédés apparentés
EP2331097A4 (fr) * 2008-08-21 2011-12-28 Richter Gedeon Nyrt Procédés de traitement de troubles du système nerveux central (cns)
ES2731228T3 (es) * 2009-01-20 2019-11-14 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico
AU2011252764B2 (en) 2010-05-14 2012-12-13 Charlotte L. Keating Neuropsychopharmacological treatment regimes for treating psychological disorders
WO2011146726A1 (fr) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Méthodes et formulations pour le traitement par l'oxytocine de troubles liés à l'utilisation de substances toxiques, de troubles psychiatriques et autres troubles
US9585935B2 (en) 2010-07-30 2017-03-07 The Regents Of The University Of California Intranasal oxytocin treatment to improve schizophrenia
CN103635190B (zh) 2011-04-04 2016-09-07 S1生物药有限公司 治疗方案

Also Published As

Publication number Publication date
HK1211239A1 (en) 2016-05-20
KR20200128437A (ko) 2020-11-12
BR112015002687A2 (pt) 2019-12-17
CA2881388A1 (fr) 2014-02-13
HK1214505A1 (zh) 2016-07-29
US20150150946A1 (en) 2015-06-04
MX2015001695A (es) 2015-09-28
SG11201500919PA (en) 2015-04-29
CN106924259A (zh) 2017-07-07
EA201590349A1 (ru) 2015-07-30
IL237150A0 (en) 2015-04-30
AU2013299725A1 (en) 2015-03-26
EP2879680A4 (fr) 2016-06-01
WO2014025814A1 (fr) 2014-02-13
EP2879680A1 (fr) 2015-06-10
US9517254B2 (en) 2016-12-13
IL237150B (en) 2018-07-31
SG10201908587PA (en) 2019-10-30
JP2015524474A (ja) 2015-08-24
KR20150063039A (ko) 2015-06-08
ZA201501562B (en) 2017-11-29
JP2018150357A (ja) 2018-09-27
AU2018205121A1 (en) 2018-07-26
CN104884060A (zh) 2015-09-02
KR20230136142A (ko) 2023-09-26

Similar Documents

Publication Publication Date Title
IL254716A0 (en) Zinc-lysine conjugate
HK1211475A1 (en) Combination therapy
GB201212513D0 (en) Therapeutic agents
EP2906208A4 (fr) Traitement thérapeutique
GB201217439D0 (en) Combination therapy
PL2838854T3 (pl) Uzdatnianie wody
EP2932922A4 (fr) Outil de traitement
GB201217704D0 (en) Therapeutic agents
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
PL2653448T3 (pl) Uzdatnianie wody
ZA201307760B (en) Treatment regimens
EP2904981A4 (fr) Outil de traitement
HK1214505A1 (zh) 治療方案
ZA201409343B (en) Water treatment
EP2804853A4 (fr) Utilisations thérapeutiques
EP2704731A4 (fr) Traitement d'origine aviaire
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201212604D0 (en) New treatment
GB201211543D0 (en) Combination therapy
GB201221326D0 (en) Novel treatments
GB201215607D0 (en) Water treatment
GB201223021D0 (en) Therapeutic agents
GB201212512D0 (en) Therapeutic agents